In The Lancet Diabetes & Endocrinology, two new reports are of particular relevance to the clinical management of primary aldosteronism.^1,2 The first, from Silvia Monticone and colleagues, is a systematic review and meta-analysis comparing patients with primary aldosteronism with those with essential hypertension at the time of presentation.¹ Although the 31 observational studies are classified as prospective or retrospective, all look backward to differences between 3838 patients with primary aldosteronism versus 9284 with essential hypertension.

中文翻译：

---

原发性醛固酮增多症和心血管风险，治疗前后

在The Lancet Diabetes & Endocrinology中，有两份新报告与原发性醛固酮增多症的临床管理特别相关。^1,2第一篇来自 Silvia Monticone 及其同事，是一项系统回顾和荟萃分析，将原发性醛固酮增多症患者与就诊时患有原发性高血压的患者进行了比较。¹尽管这 31 项观察性研究被归类为前瞻性或回顾性研究，但所有研究都回顾了 3838 名原发性醛固酮增多症患者与 9284 名原发性高血压患者之间的差异。